Seragen, Inc.
🏢 View company profile →9Patents
0Active
9Granted
28Portfolio score
Filing activity: Mar 2, 1990 → May 5, 1997
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5668255A | Hybrid molecules having translocation region and cell-binding region | Chemistry; Metallurgy | 122 | Expired |
| US6022950A | Hybrid molecules having translocation region and cell-binding region | Chemistry; Metallurgy | 84 | Expired |
| US6074636A | Method of using cell surface receptor targeted molecules for the treatment of viral diseases | Chemistry; Metallurgy | 78 | Expired |
| US5965406A | Recombinant DNAS encoding three-part hybrid proteins | Chemistry; Metallurgy | 44 | Expired |
| US5906820A | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis | Chemistry; Metallurgy | 14 | Expired |
| US5614488A | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis | Chemistry; Metallurgy | 10 | Expired |
| US5571507A | Methods of treating diabetes | Chemistry; Metallurgy | 8 | Expired |
| US5110912A | Purification of Il-2-containing hybrid compounds | Chemistry; Metallurgy | 1 | Expired |
| US5684221A | Mammalian model of a malignant disorder | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.